Halozyme Therapeutics financials
$111.56−1.18%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.40B | $1.02B | $829.3M | $660.1M | $443.3M | $267.6M | $196.0M | $151.9M | $316.6M | $146.7M |
| Gross profit | $1.17B | $855.9M | $636.9M | $520.8M | $361.9M | $224.2M | $150.4M | $141.7M | $285.5M | $113.5M |
| Gross margin | 83.6% | 84.3% | 76.8% | 78.9% | 81.6% | 83.8% | 76.8% | 93.3% | 90.2% | 77.4% |
| Operating income | $517.7M | $551.5M | $337.6M | $267.5M | $275.9M | $144.3M | -$67.6M | -$69.3M | $81.0M | -$83.2M |
| Net income | $316.9M | $444.1M | $281.6M | $202.1M | $402.7M | $129.1M | -$72.2M | -$80.3M | $63.0M | -$103.0M |
| Net margin | 22.7% | 43.7% | 34.0% | 30.6% | 90.8% | 48.2% | −36.9% | −52.9% | 19.9% | −70.2% |
| Diluted EPS | $2.56 | $3.43 | $2.10 | $1.44 | $2.74 | $0.91 | $-0.50 | $-0.56 | $0.45 | $-0.81 |
| EBITDA | $890.6M | $632.8M | $422.4M | $317.2M | $278.9M | $147.5M | -$63.5M | -$66.9M | $83.2M | -$80.8M |
| Operating cash flow | $651.6M | $479.1M | $388.6M | $240.1M | $299.4M | $55.5M | -$85.4M | -$49.5M | $134.1M | -$50.4M |
| Free cash flow | $644.6M | $468.4M | $373.3M | $235.3M | $298.0M | $53.0M | -$89.5M | -$54.2M | $132.7M | -$53.5M |
| Diluted shares | 123.9M | 129.4M | 134.2M | 140.6M | 146.8M | 141.5M | 144.3M | 143.6M | 139.1M | 128.0M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $133.8M | $115.8M | $118.4M | $234.2M | $118.7M | $147.7M |
| Short-term investments | $9.0M | $480.2M | $217.6M | $128.6M | $622.2M | $220.3M |
| Total debt | $2.14B | $1.51B | $1.50B | $1.51B | $876.7M | $397.2M |
| Total assets | $2.53B | $2.06B | $1.73B | $1.84B | $1.10B | $579.9M |
| Total liabilities | $2.48B | $1.70B | $1.65B | $1.67B | $907.5M | $428.9M |
| Shareholders' equity | $48.8M | $363.8M | $83.8M | $169.8M | $197.0M | $151.0M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology